- Short Communication
Cyclic phosphatidic acid induces G0/G1 arrest, inhibits Akt phosphorylation, and downregulates cyclin D1 expression in colorectal cancer cells
Cellular & Molecular Biology Letters (2014)
Lysophosphatidic acid (LPA) and its analogs are well-known mitogens for various cell types. Many reports have confirmed that several types of cancer cell produce LPA to promote survival, growth and tumorigenesis. This indicates that the interface between the LPA signaling pathway and the cell cycle signaling system is critical to the control of cancer cell proliferation. However, our previous study indicated that cyclic phosphatidic acid (cPA), which is structurally similar to LPA, inhibits the proliferation and migration of colon cancer cells. It has been reported that cPA shows several biological activities not shown by LPA. However, understanding of the detailed molecular and cellular mechanism underlying the regulation of the cell cycle by cPA is still in its infancy. In this study, we investigated the effect of cPA treatment on human DLD-1 colon cancer cells by analyzing cell cycle dynamics, gene expression, and AKT phosphorylation. Our findings indicate that cPA inhibits cell cycle progression in DLD-1 colon cancer cells via the downregulation of cyclin D1 and the inhibition of AKT phosphorylation.
cyclic phosphatidic acid
Dulbecco’s modified Eagle’s medium
fetal bovine serum
phosphoinositide 3 kinase
sodium dodecyl sulfate
Morgan, D.O. Principles of CDK regulation. Nature 374 (1995) 131–134.
Satyanarayana, A. and Kaldis, P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28 (2009) 2925–2939.
Murray, A.W. Recycling the cell cycle: cyclins revisited. Cell 116 (2004) 221–234.
Zhang, T., Nanney, L.B., Luongo, C., Lamps, L., Heppner, K.J., DuBois, R.N. and Beauchamp, R.D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 57 (1997) 169–175.
Motokura, T., Bloom, T., Kim, H.G., Juppner, H., Ruderman, J.V., Kronenberg, H.M. and Arnold, A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350 (1991) 512–515.
Xiong, Y., Connolly, T., Futcher, B. and Beach, D. Human D-type cyclin. Cell 65 (1991) 691–699.
Matsushime, H., Roussel, M.F., Ashmun, R.A. and Sherr, C.J. Colonystimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65 (1991) 701–713.
Arnold, A. and Papanikolaou, A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23 (2005) 4215–4224.
Huang, S., Chen, C.S. and Ingber, D.E. Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol. Biol. Cell 9 (1998) 3179–3193.
Arber, N., Doki, Y., Han, E.K., Sgambato, A., Zhou, P., Kim, N.H., Delohery, T., Klein, M.G., Holt, P.R. and Weinstein, I.B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57 (1997) 1569–1574.
Bartkova, J., Lukas, J., Strauss, M. and Bartek, J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer 58 (1994) 568–573.
Takahashi, Y., Shimada, Y., Shioda, M., Yoshida, S., Murofushi, H. and Murakami-Murofushi, K. Isolation of a new species of Physarum lysophosphatidic acid, PHYLPA, and its effect on DNA polymerase activity. Cell Struct. Funct. 18 (1993) 135–138.
Tsukahara, T. The role of PPARgamma in the transcriptional control by agonists and antagonists. PPAR Res. 2012 (2012) 362361.
Tsukahara, T. PPAR gamma networks in cell signaling: update and impact of cyclic phosphatidic acid. J. Lipids 2013 (2013) 246597.
Murakami-Murofushi, K., Uchiyama, A., Fujiwara, Y., Kobayashi, T., Kobayashi, S., Mukai, M., Murofushi, H. and Tigyi, G. Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim. Biophys. Acta 1582 (2002) 1–7.
Tsukahara, T., Hanazawa, S., Kobayashi, T., Iwamoto, Y. and Murakami-Murofushi, K. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor gamma. Prostaglandins Other Lipid Mediat. 93 (2010) 126–133.
Levine, J.S., Koh, J.S., Triaca, V. and Lieberthal, W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am. J. Physiol. 273 (1997) F575–585.
Domin, J. and Waterfield, M.D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett. 410 (1997) 91–95.
Sun, H., Ren, J., Zhu, Q., Kong, F.Z., Wu, L. and Pan, B.R. Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. World J. Gastroenterol. 15 (2009) 4547–4555.
Tsukahara, T., Tsukahara, R., Fujiwara, Y., Yue, J., Cheng, Y., Guo, H., Bolen, A., Zhang, C., Balazs, L., Re, F., Du, G., Frohman, M.A., Baker, D.L., Parrill, A.L., Uchiyama, A., Kobayashi, T., Murakami-Murofushi, K. and Tigyi, G. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol. Cell 39 (2010) 421–432.
Baker, D.L., Fujiwara, Y., Pigg, K.R., Tsukahara, R., Kobayashi, S., Murofushi, H., Uchiyama, A., Murakami-Murofushi, K., Koh, E., Bandle, R.W., Byun, H.S., Bittman, R., Fan, D., Murph, M., Mills, G.B. and Tigyi, G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J. Biol. Chem. 281 (2006) 22786–22793.
Tigyi, G., Dyer, D.L. and Miledi, R. Lysophosphatidic acid possesses dual action in cell proliferation. Proc. Natl. Acad. Sci. USA 91 (1994) 1908–1912.
McKay, J.A., Douglas, J.J., Ross, V.G., Curran, S., Murray, G.I., Cassidy, J. and McLeod, H.L. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int. J. Cancer 88 (2000) 77–81.
Sherr, C.J., Matsushime, H. and Roussel, M.F. Regulation of CYL/cyclin D genes by colony-stimulating factor 1. Ciba Found Symp. 170 (1992) 209–219; discussion 219–226.
Aggarwal, P., Lessie, M.D., Lin, D.I., Pontano, L., Gladden, A.B., Nuskey, B., Goradia, A., Wasik, M.A., Klein-Szanto, A.J., Rustgi, A.K., Bassing, C.H. and Diehl, J.A. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 21 (2007) 2908–2922. Hu, Y.L., Albanese, C., Pestell, R.G. and Jaffe,R.B. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J. Natl. Cancer Inst. 95 (2003) 733–740.
Fujiwara, Y. Cyclic phosphatidic acid — a unique bioactive phospholipid. Biochim. Biophys. Acta 1781 (2008) 519–524.
Kampa-Schittenhelm, K.M., Heinrich, M.C., Akmut, F., Rasp, K.H., Illing, B., Dohner, H., Dohner, K. and Schittenhelm, M.M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol. Cancer 12 (2013) 46.
Rights and permissions
About this article
Cite this article
Tsukahara, T., Haniu, H. & Matsuda, Y. Cyclic phosphatidic acid induces G0/G1 arrest, inhibits Akt phosphorylation, and downregulates cyclin D1 expression in colorectal cancer cells. Cell Mol Biol Lett (2014). https://doi.org/10.2478/s11658-014-0224-2
- Cyclic phosphatidic acid
- Lysophosphatidic acid
- Colon cancer cells
- Cell cycle analysis
- Cell proliferation
- Cyclin D1
- Akt phosphorylation
- Cancer treatment